{Reference Type}: Journal Article
{Title}: [Is monitoring of anti-factor Xa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?]
{Author}: Ding M;Ning Y;Song L;Li P;Xie F;Li S;Wang C;
{Journal}: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
{Volume}: 36
{Issue}: 5
{Year}: 2024 May
暂无{DOI}: 10.3760/cma.j.cn121430-20231103-00937
{Abstract}: The incidence and mortality of venous thromboembolism (VTE) are high in critically ill patients, and there is still a risk of VTE and bleeding after the use of fixed-dose low molecular weight heparin (LMWH) for prophylaxis. The level of anti-factor Xa is not up to standard after LMWH prophylaxis in patients with surgery or trauma. The condition of critically ill patients is complicated, and the proportion of patients with low antithrombin III is high, which can affect the prophylactic efficacy of LMWH and contribute to VTE occurrence. There is currently no consensus on whether adjusting LMWH dose according to anti-factor Xa levels can reduce VTE occurrence in critically ill patients. High-quality multicenter randomized controlled studies are needed in the future to establish new approaches for precise prevention of VTE in critically ill patients.